RNA interference targeting the R2 subunit of ribonucleotide reductase inhibits growth of tumor cells in vitro and in vivo

@article{Avolio2007RNAIT,
  title={RNA interference targeting the R2 subunit of ribonucleotide reductase inhibits growth of tumor cells in vitro and in vivo},
  author={Tina Avolio and Y. Lee and Ningping Feng and K. Xiong and Hongnan Jin and M. Wang and A. Vassilakos and Jim A. Wright and A. Young},
  journal={Anti-Cancer Drugs},
  year={2007},
  volume={18},
  pages={377-388}
}
RNA interference, a posttranscriptional gene-silencing mechanism, has received considerable attention for its potential as a new therapeutic strategy to treat human diseases and conditions including cancer. Various studies have supported a role for the R2 subunit of ribonucleotide reductase in cancer progression and metastasis. Short interfering siRNA 1284 was designed to target R2. In vitro studies, in which three different human tumor cell lines (A498, HT-29 and A2058) were transfected with… Expand
siRNA knockdown of ribonucleotide reductase inhibits melanoma cell line proliferation alone or synergistically with temozolomide.
Systemically delivered small interfering RNA (siRNA) therapies for cancer have begun clinical development. The effects of siRNA-mediated knockdown of ribonucleotide reductase subunit-2 (RRM2), aExpand
Potent subunit-specific effects on cell growth and drug sensitivity from optimised siRNA-mediated silencing of ribonucleotide reductase
TLDR
Results suggest that RRM1 is a potential target for nucleic acid-based cancer therapies, either alone or in combination with gemcitabine, and suggest that the inhibition of cell growth, rather than drug sensitization, is the major effect of RRM 1 and RRM2 knockdown. Expand
Clinical pharmacology and clinical trials of ribonucleotide reductase inhibitors: is it a viable cancer therapy?
TLDR
RR inhibitors are viable treatment options, either as a monotherapy or as a combination in cancer chemotherapy, with the recent advances made in cancer biology. Expand
Ribonucleotide reductase and cancer: biological mechanisms and targeted therapies
TLDR
How a key regulator of dNTP biosynthesis in mammals, the enzyme ribonucleotide reductase (RNR), impacts cancer susceptibility and serves as a target for anti-cancer therapies is discussed. Expand
RNA Interference Characterization of Proteins Discovered by Proteomic Analysis of Pancreatic Cancer Reveals Function in Cell Growth and Survival
TLDR
By combining a mass spectrometry identification platform and an RNAi validation platform, a panel of cell surface glycoproteins that not only are overexpressed, but also play a functional role in pancreatic tumor cell survival are identified. Expand
Impact of tumor‐specific targeting and dosing schedule on tumor growth inhibition after intravenous administration of siRNA‐containing nanoparticles
TLDR
Mathematical model calculations of siRNA‐mediated target protein knockdown and tumor growth inhibition are used to elucidate possible mechanisms to explain the observed effects and to provide guidelines for designing more effective si RNA‐based treatment regimens regardless of delivery methodology and tumor type. Expand
Targeting Tumors and the Kidney with siRNA Nanoparticles and Evaluation of Extracellular MicroRNA-based Methodologies to Track Their Activity
TLDR
This thesis work focuses on efforts to characterize microRNA expression patterns following pharmacologic inhibition of the oncogene BRAF in melanoma cells and their secreted exosomes and test the hypothesis that analysis of tumor-secreted microRNAs within patient blood samples can be used as real-time markers of drug pharmacodynamics. Expand
A microfluidic method to synthesize transferrin-lipid nanoparticles loaded with siRNA LOR-1284 for therapy of acute myeloid leukemia.
TLDR
Results suggest that Tf-conjugated NPs prepared by MHF provide a suitable platform for efficient and specific therapeutic delivery of LOR-1284 into acute myeloid leukemia (AML) cells. Expand
Non-covalent complexes of folic acid and oleic acid conjugated polyethylenimine: An efficient vehicle for antisense oligonucleotide delivery.
TLDR
This novel formulation of FA/PEI-OA provides a reliable and highly efficient method for delivery of oligonucleotide and warrants further investigation. Expand
Evaluation of mRNA by Q-RTPCR and protein expression by AQUA of the M2 subunit of ribonucleotide reductase (RRM2) in human tumors
TLDR
RRM2 gene and protein expression varies by tumor type, and baseline RRM2 protein and gene expression in patients receiving 3-AP is evaluated. Expand
...
1
2
...

References

SHOWING 1-10 OF 91 REFERENCES
RNA interference targeting the M2 subunit of ribonucleotide reductase enhances pancreatic adenocarcinoma chemosensitivity to gemcitabine
TLDR
It is shown that RRM2 overexpression is associated with gemcitabine chemoresistance in pancreatic adenocarcinoma cells, and that suppression ofRRM2 expression using RNA interference mediated by small interfering RNA (siRNA) enhances gem citabine-induced cytotoxicity in vitro. Expand
Prospects of RNA interference therapy for cancer
TLDR
Major obstacles, such as in vivo delivery, incomplete suppression of target genes, nonspecific immune responses and the so-called off-target effects, need to be overcome before this technology can be successfully translated into the clinical arena. Expand
Retrovirally mediated RNA interference targeting the M2 subunit of ribonucleotide reductase: A novel therapeutic strategy in pancreatic cancer.
TLDR
RRM2 gene silencing attenuates pancreatic adenocarcinoma cellular invasiveness and gemcitabine chemoresistance and can efficiently induce stable RNAi, allowing dissection of gene function and potentially representing a new therapeutic modality. Expand
GTI-2040, an antisense agent targeting the small subunit component (R2) of human ribonucleotide reductase, shows potent antitumor activity against a variety of tumors.
TLDR
The results of these studies indicate that GTI-2040 can act as a selective and specific anticancer agent against a broad range of human tumors. Expand
Ribonucleotide reductase R2 component is a novel malignancy determinant that cooperates with activated oncogenes to determine transformation and malignant potential.
  • H. Fan, C. Villegas, J. Wright
  • Biology, Medicine
  • Proceedings of the National Academy of Sciences of the United States of America
  • 1996
TLDR
These studies demonstrate that the R2 protein can participate in other critical cellular functions in addition to ribonucleotide reduction, and that deregulated R2 is a novel tumor progressor determinant that cooperates in oncogene-mediated mechanisms, which control malignant potential. Expand
Overexpression of the R2 Subunit of Ribonucleotide Reductase in Human Nasopharyngeal Cancer Cells Reduces Radiosensitivity
TLDR
An increase in R2 protein levels and RR activity in KB/M2 cells results in IR resistance, which appears mediated by enhanced IR damage repair during G2, a finding that correlates with increased reparable IR damage. Expand
Comparison of the suppressive effects of antisense oligonucleotides and siRNAs directed against the same targets in mammalian cells.
TLDR
A comparative analysis of the suppressive effects of three knockdown methods, namely, methods based on RNA interference (RNAi), antisense ODNs, and ribozymes, using a luciferase reporter system provides useful information about the positional effects in RNAi, which might help to improve the design of effective siRNAs. Expand
Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs
TLDR
It is shown that chemically modified short interfering RNAs (siRNAs) can silence an endogenous gene encoding apolipoprotein B (apoB) after intravenous injection in mice, and it is determined that cleavage of the apoB mRNA occurred specifically at the predicted site. Expand
Flavopiridol increases sensitization to gemcitabine in human gastrointestinal cancer cell lines and correlates with down-regulation of ribonucleotide reductase M2 subunit.
  • C. Jung, M. Motwani, G. Schwartz
  • Biology, Medicine
  • Clinical cancer research : an official journal of the American Association for Cancer Research
  • 2001
TLDR
Flavopiridol, a cyclin-dependent kinase inhibitor, enhances the induction of apoptosis by gemcitabine in human pancreatic, gastric, and colon cancer cell lines and indicates that flavopiridsol in gem citabine-treated cells inhibits parts of the machinery necessary for the transcription induction of RR-M2. Expand
Ribonucleotide reductase R2 gene expression and changes in drug sensitivity and genome stability.
TLDR
It is hypothesized that altered expression of the R2 component is capable of significantly modifying drug sensitivity properties of tumor cells through a mechanism of increased genetic instability that is independent of direct p53 mutation or loss and involves R2 stimulation of the mitogen-activated protein kinase signal pathway. Expand
...
1
2
3
4
5
...